Daxor Corporation Receives $300K Matching Fund Award
This SBIR Matching Fund Award Will Boost Our Innovation, Commercialization Efforts, and Job Creation
Oak Ridge, TN — Daxor Corporation (NASDAQ: DXR), a leader in blood volume measurement technology, has been awarded a significant $300,000 SBIR matching fund by Launch Tennessee (LaunchTN). This funding is intended to accelerate the development of Daxor’s next-generation point-of-care blood volume analyzer, enhancing their capabilities following a Phase II award from the Defense Health Agency.
Influence on Innovation and Community
Michael Feldschuh, Daxor's CEO and President, shared his excitement about the funding: “This award significantly enhances our portfolio of non-dilutive funding. It allows us to equip clinicians with advanced tools for effective fluid management, which is essential for improving patient outcomes.” His statement reflects Daxor's strong commitment to innovation and job creation within the local community.
The Role of Launch Tennessee
LaunchTN is a strategic public-private partnership dedicated to promoting entrepreneurship and economic growth in Tennessee. Their goal is to position Tennessee as the leading state for startups by offering essential resources for technology development, workforce training, and access to capital. Daxor’s recent award is a clear indication of its commitment to expanding its operations in Tennessee.
About Daxor Corporation
Established as a frontrunner in blood volume measurement, Daxor Corporation (Nasdaq: DXR) focuses on innovations in blood volume testing. Their flagship product, the BVA-100™, is the only FDA-cleared diagnostic blood test that accurately measures blood volume status and composition against patient-specific norms. With over 65,000 successful tests conducted in top hospitals across the country, Daxor plays a crucial role in improving healthcare outcomes, particularly in lowering mortality and readmission rates in heart failure and critical care environments.
Ongoing Growth and Research Initiatives
Daxor is actively involved in several clinical trials targeting heart failure treatment, with support from the National Institutes of Health (NIH). They are also partnering with the U.S. Department of Defense to develop analyzers aimed at improving care for combat casualties. Daxor’s mission remains steadfast: to transform healthcare through precise blood volume analysis, ensuring optimal blood volume for every patient.
Connect with Daxor Corporation
For further information about Daxor's advancements in blood volume measurement, interested individuals are encouraged to visit their website. The company is open to inquiries and welcomes those interested in signing up for news about their innovative technologies.
Frequently Asked Questions
What is the recent funding Daxor Corporation received for?
Daxor Corporation received a $300K matching fund from Launch Tennessee to advance their next-generation blood volume analyzer.
What does Daxor Corporation specialize in?
Daxor Corporation specializes in blood volume measurement technology, offering the BVA-100™, the only FDA-cleared diagnostic blood test for blood volume analysis.
How does Launch Tennessee support companies like Daxor?
Launch Tennessee supports companies by providing access to capital, mentorship, and resources aimed at enhancing entrepreneurship and economic development in the state.
What is the significance of Daxor's products?
Daxor’s products are vital for optimal fluid management in clinical settings, improving patient outcomes and reducing mortality rates in critical care.
How can I learn more about Daxor Corporation?
To learn more, visit Daxor’s website for detailed information and to stay updated on their innovative technologies.
